Amgen Targets Hikma, Organon in Fresh Prolia, Xgeva Patent Suits

Amgen Inc. filed lawsuits in New Jersey federal court separately accusing two pairs of companies of infringing more than two dozen patents each with proposed biosimilars of its Prolia and Xgeva bone drugs.

RGB-14-P and RGB-14-X—biosimilars of Prolia and Xgeva developed by Gedeon Richter Plc and licensed to a Hikma Pharmaceuticals Plc unit for US marketing—infringe 32 Amgen patents covering denosumab, the antibody active in both drugs, along with methods for producing and formulating it, according to a complaint filed Wednesday in the US District Court for the District of New Jersey.

A separate complaint also filed Wednesday alleges that ...